DK2024347T3 - Phenylamino-benzoxazol substituerede carboxylsyrer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel - Google Patents

Phenylamino-benzoxazol substituerede carboxylsyrer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel

Info

Publication number
DK2024347T3
DK2024347T3 DK07724733.6T DK07724733T DK2024347T3 DK 2024347 T3 DK2024347 T3 DK 2024347T3 DK 07724733 T DK07724733 T DK 07724733T DK 2024347 T3 DK2024347 T3 DK 2024347T3
Authority
DK
Denmark
Prior art keywords
phenylamino
medicine
procedure
preparation
carboxylic acids
Prior art date
Application number
DK07724733.6T
Other languages
Danish (da)
English (en)
Inventor
Elisabeth Defossa
Thomas Klabunde
Viktoria Drosou
Gerhard Hessler
Siegfried Stengelin
Guido Haschke
Andreas Herling
Stefan Bartoschek
Markus Follmann
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK2024347T3 publication Critical patent/DK2024347T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK07724733.6T 2006-05-11 2007-04-30 Phenylamino-benzoxazol substituerede carboxylsyrer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel DK2024347T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2007/003806 WO2007131622A1 (de) 2006-05-11 2007-04-30 Phenylamino-benzoxazol substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
DK2024347T3 true DK2024347T3 (da) 2012-10-29

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07724733.6T DK2024347T3 (da) 2006-05-11 2007-04-30 Phenylamino-benzoxazol substituerede carboxylsyrer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel

Country Status (30)

Country Link
US (2) US20090149519A1 (cg-RX-API-DMAC7.html)
EP (1) EP2024347B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009536629A (cg-RX-API-DMAC7.html)
KR (1) KR20090006846A (cg-RX-API-DMAC7.html)
CN (1) CN101437805B (cg-RX-API-DMAC7.html)
AR (1) AR060990A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007250213B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711448A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651660A1 (cg-RX-API-DMAC7.html)
CO (1) CO6241107A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113177T1 (cg-RX-API-DMAC7.html)
DE (1) DE102006021878A1 (cg-RX-API-DMAC7.html)
DK (1) DK2024347T3 (cg-RX-API-DMAC7.html)
ES (1) ES2391203T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120829T1 (cg-RX-API-DMAC7.html)
IL (1) IL195179A0 (cg-RX-API-DMAC7.html)
MA (1) MA30402B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008014102A (cg-RX-API-DMAC7.html)
MY (1) MY148258A (cg-RX-API-DMAC7.html)
NO (1) NO20085068L (cg-RX-API-DMAC7.html)
NZ (1) NZ572692A (cg-RX-API-DMAC7.html)
PL (1) PL2024347T3 (cg-RX-API-DMAC7.html)
PT (1) PT2024347E (cg-RX-API-DMAC7.html)
RS (1) RS52450B (cg-RX-API-DMAC7.html)
RU (1) RU2434003C2 (cg-RX-API-DMAC7.html)
SI (1) SI2024347T1 (cg-RX-API-DMAC7.html)
TW (1) TW200812987A (cg-RX-API-DMAC7.html)
UY (1) UY30338A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007131622A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200808490B (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
ES2446419T3 (es) 2007-04-16 2014-03-07 Amgen, Inc Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
US8716283B2 (en) 2007-11-07 2014-05-06 University Of Massachusetts Type III secretion inhibitors, analogs and uses thereof
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2011140190A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Tetrazolones as inhibitors of fatty acid synthase
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201317229A (zh) * 2011-09-14 2013-05-01 Daiichi Sankyo Co Ltd 稠合雜環衍生物
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
CN118084940A (zh) 2018-02-13 2024-05-28 吉利德科学公司 Pd-1/pd-l1抑制剂
AU2019255750B2 (en) 2018-04-19 2021-10-21 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
US11976052B2 (en) 2019-01-11 2024-05-07 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491863A (en) * 1973-10-23 1977-11-16 Lilly Industries Ltd 2,5-or 2,6-disubstituted benzoxazoles
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
DE69327536T2 (de) * 1992-10-14 2000-07-06 Merck & Co., Inc. Fibrinogenrezeptor-antagonisten
PT966465E (pt) * 1997-03-14 2003-11-28 Vertex Pharma Inibidores do enzima imfdh
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
CA2362862A1 (en) * 1999-02-16 2000-08-24 Aventis Pharma Limited Bicyclic compounds and their use as integrin receptor ligands
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
MXPA03003829A (es) * 2000-11-04 2003-07-28 Aventis Pharma Ltd Acidos alcanoicos substituidos.
CA2430978C (en) * 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Also Published As

Publication number Publication date
WO2007131622A1 (de) 2007-11-22
RU2434003C2 (ru) 2011-11-20
MX2008014102A (es) 2008-11-14
US20090149519A1 (en) 2009-06-11
CO6241107A2 (es) 2011-01-20
HK1131978A1 (en) 2010-02-12
NO20085068L (no) 2009-02-04
PT2024347E (pt) 2012-10-09
EP2024347B1 (de) 2012-08-01
AR060990A1 (es) 2008-07-30
BRPI0711448A2 (pt) 2011-11-08
KR20090006846A (ko) 2009-01-15
IL195179A0 (en) 2009-08-03
AU2007250213A1 (en) 2007-11-22
MY148258A (en) 2013-03-29
ZA200808490B (en) 2009-10-28
CY1113177T1 (el) 2016-04-13
CN101437805A (zh) 2009-05-20
CA2651660A1 (en) 2007-11-22
EP2024347A1 (de) 2009-02-18
AU2007250213B2 (en) 2013-04-11
DE102006021878A1 (de) 2007-11-15
PL2024347T3 (pl) 2013-01-31
UY30338A1 (es) 2008-01-02
NZ572692A (en) 2011-03-31
US20130303578A1 (en) 2013-11-14
CN101437805B (zh) 2012-05-30
SI2024347T1 (sl) 2012-11-30
JP2009536629A (ja) 2009-10-15
RS52450B (sr) 2013-02-28
HRP20120829T1 (hr) 2012-11-30
RU2008148838A (ru) 2010-06-20
ES2391203T3 (es) 2012-11-22
TW200812987A (en) 2008-03-16
MA30402B1 (fr) 2009-05-04
US8748465B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
DK2024347T3 (da) Phenylamino-benzoxazol substituerede carboxylsyrer, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
DK2327694T3 (da) Substituerede 4-aminopicolinsyrer og deres anvendelse som herbicider
NO2018019I2 (no) Ertugliflozin, eventuelt som en krystallform, særlig som en ko-krystall med L-pyroglutaminsyre, og spesielt som Ertugliflozin L-pyroglutaminsyre
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
DK2350026T3 (da) Sulfoximinsubstituerede anilinopyrimidinderativer som cdk-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
DK2373716T3 (da) Cyclohexanpolycarboxylsyrederivater som blødgørere til klæbe- og tætningsmasse
NO2016014I2 (no) ceritinib eller farmasøytisk akseptable salter derav
DK3323462T3 (da) Næsepuder til en patientgrænseflade.
DK1711494T3 (da) Arylsubstituerede heterocykler, fremgangsmåde til deres fremstilling og deres anvendelse som lægemiddel
HUE062920T2 (hu) Eljárások vakcina beadására
DK2197849T3 (da) N-(pyrazol-3-yl)-benzamidderivater som glucosinaseaktivatorer
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
IL196024A0 (en) Influenza vaccine
DK2059513T3 (da) Fremgangsmåde til fremstillingen af 1,2,4-oxadiazolbenzoesyrer
DK1991091T3 (da) Sikkerhedsbøjle til en barnestol
EP2052757A4 (en) MEDICAL CAPSULE
DK1871181T3 (da) Kosttilskud til HIV-patienter
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
DK1978981T3 (da) Præparater til vaginal anvendelse
DK2240487T3 (da) Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
DK2240482T3 (da) Cykliske azaindol-3-carboxamider, deres fremstilling og deres anvendelse som lægemidler
PL2422810T3 (pl) Szczepionka przeciw grypie
FI20065089A0 (fi) Menetelmä yhdistelmäsuolen valmistamiseksi
DK1718340T3 (da) Nye effektorkonjugater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
DK1816121T3 (da) 9-chlor-15-deoxyprostaglandinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som medikamenter